PegBio Co., Ltd.
派格生物醫藥(杭州)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2565)

VOLUNTARY ANNOUNCEMENT
Research Abstract Related to CR059 Accepted by the 2026 Scientific Sessions of the American Diabetes Association and Selected as a Late Breaking Abstract

This announcement is made by PegBio Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis for the purpose of keeping the shareholders of the Company and potential investors abreast of the latest business development of the Group.

The board (the "**Board**") of directors of the Company is pleased to announce that the research abstract related to CR059, an innovative product candidate independently developed by the Group, has been accepted by the 2026 Scientific Sessions of the American Diabetes Association (ADA) and selected as a Late Breaking Abstract, which will be displayed as a poster presentation. The relevant abstract is entitled: CR059, a Once-Monthly circRNA-Encoded GLP-1 Analogue, Demonstrates Durable Glycemic Control in T2D Rhesus Monkeys.

CR059 is an innovative product candidate independently developed by the Group. According to the relevant research results, CR059 demonstrated significant weight-loss efficacy, outstanding glucose-lowering performance, and long-term expression characteristics, showing its development potential as a long-acting therapeutic regimen for metabolic diseases. The abstract also indicates that, based on the circRNA-LNP technology platform, CR059 is expected to achieve monthly dosing, or even be extended to quarterly dosing, and supports sustained expression and long-acting metabolic control.

The Scientific Sessions of the ADA is one of the internationally influential academic conferences in the field of diabetes and metabolic diseases. The Board considers that the acceptance of the CR059-related research abstract and its selection as a Late Breaking Abstract reflect the attention of the international academic community towards the Group's latest progress in innovative research and development in the field of metabolic diseases. It will help enhance the international academic influence of the CR059 project and strengthen the market's recognition of the Group's innovative research and development capabilities and the value of its technology platform.

According to the conference schedule, the aforementioned research abstract will be presented in the form of a poster during the 2026 Scientific Sessions of the ADA.

The Company will continue to advance the research and development of CR059 and other innovative pipelines, and will make further announcements as and when appropriate in accordance with the requirements of applicable laws, regulations and the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") .

As CR059 is currently still in the research and development stage, there remains uncertainties in the subsequent research and development, clinical trial progress, registration and approval, and commercialization of the product candidate. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
PegBio Co., Ltd.
Michael Min XU
Chairman of the Board, Executive Director and General Manager

Hong Kong, April 2, 2026

As of the date of this announcement, the Board of the Company comprises: (i) Dr. Michael Min XU and Ms. Xiaojun WANG as executive directors; (ii) Dr. Xiangjun ZHOU, Dr. Yuhong XU, Ms. Ting ZHAI and Mr. Hongkai LI as non-executive directors; and (iii) Dr. Jiancun ZHANG, Dr. Yangyang CHEN and Ms. Xinpeng FAN as independent non-executive directors.